Old Web
English
Sign In
Acemap
>
authorDetail
>
Sarah Hu
Sarah Hu
Bristol-Myers Squibb
Medicine
Oncology
Internal medicine
Nivolumab
Taxane
3
Papers
62
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
THU0239 IDENTIFICATION OF BIOMARKERS AND IMMUNE PATHWAYS FOR PERSONALIZED DRUG TARGETING IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY SJÖGREN’S SYNDROME
2019
Annals of the Rheumatic Diseases
Gwenny M. Verstappen
Lu Gao
Sarah Pringle
Janneke H. Terpstra
Silvia C Liefers
Jolien F. van Nimwegen
Arjan Vissink
Vishal Patel
Aiqing He
Amy Truong
Sarah Hu
Ashok Dongre
Arathi Krishnakumar
Stefan Kirov
Julie Carman
Hendrika Bootsma
Frans G. M. Kroese
Show All
Source
Cite
Save
Citations (0)
Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
2019
Journal of Clinical Oncology
Padmanee Sharma
Russell Pachynski
Vivek Narayan
Aude Flechon
Gwenaelle Gravis
Matthew D. Galsky
Hakim Mahammedi
Akash Patnaik
Sumit K. Subudhi
Marika Ciprotti
Tao Duan
Abdel Saci
Sarah Hu
G. Celine Han
Karim Fizazi
Show All
Source
Cite
Save
Citations (62)
1